share_log

HC Wainwright & Co. Initiates Coverage On Emergent BioSolutions With Buy Rating, Announces Price Target of $15

HC Wainwright & Co. Initiates Coverage On Emergent BioSolutions With Buy Rating, Announces Price Target of $15

HC Wainwright & Co. 对Emergent BioSolutions进行覆盖分析,给予买入评级,宣布价格目标为15美元。
Benzinga ·  2024/12/30 06:57  · 评级/大行评级

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Emergent BioSolutions (NYSE:EBS) with a Buy rating and announces Price Target of $15.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱以买入评级开始报道Emergent BioSolutions(纽约证券交易所代码:EBS),并宣布目标股价为15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发